Ixazomib Citrate

5 trials LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

4 Completed trials

7 Sponsors

12 Countries

Phase III

Phase II

Phase III: 2 Phase II: 3

Sponsors using this IMP

Celgene Corp. 1 Centre Hospitalier Universitaire De Nantes 1 Ceska Myelomova Skupina z.s. 1 Emn Trial Office S.r.l. Impresa Sociale 1 European Myeloma Network B.V. 1 HUS-Yhtymae 1 University Medical Center Hamburg-Eppendorf 1

All trials

5 total

A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse Pending

2024-516257-44-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd… Ended

2024-511781-37-00 Phase II 3 countries Ceska Myelomova Skupina z.s.; Emn Trial Office S.r.l. Impresa Sociale; European …
A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended

2024-517321-99-00 Phase II 4 countries HUS-Yhtymae
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended

2024-510590-14-00 Phase III 1 country University Medical Center Hamburg-Eppendorf
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended

2023-509848-10-00 Phase III 7 countries Celgene Corp.

Showing 1–5 of 5 trials

← All drugs A–Z